目的检测Robo1蛋白在不同乳腺肿瘤组织中的表达情况,并探讨Robo1蛋白的表达与乳腺癌脑转移的关系。方法采用链霉素抗生物素蛋白-生物素(LSAB)法,对24例发生脑转移的乳腺浸润性导管癌、71例未发生脑转移的乳腺浸润性导管癌、22例乳腺导管内癌和23例乳腺纤维腺瘤组织中Robo1蛋白的表达情况进行检测。结果Robo1蛋白在导管内癌和浸润性导管癌组织中的阳性表达率分别为59.1%和45.3%,均明显低于其在纤维腺瘤组织中的阳性表达率(87.0%,P〈0.05)。Robo1蛋白在有脑转移的浸润性导管癌组织中的阳性表达率为12.5%,明显低于其在无脑转移的浸润性导管癌中的阳性表达率(56.3%,P〈0.05)。Robo1蛋白在〉50岁乳腺浸润性导管癌患者中的阳性表达率为57.8%,明显高于其在≤50岁乳腺浸润性导管癌患者中的阳性表达率(34.0%,P〈0.05)。Robo1蛋白阴性表达患者的5年生存率为57.7%,明显低于阳性表达的患者(83.7%,P〈0.05)。Robo1蛋白在乳腺浸润性导管癌中的表达与肿瘤大小、淋巴结转移状态、病理学分期、组织学分级以及临床分期均无关(均P〉0.05)。结论Robo1蛋白在乳腺浸润性导管癌中的表达与脑转移呈负相关,与患者的发病年龄及预后呈正相关,可成为判断乳腺癌预后和脑转移的分子标志物。
Objective To detect the expression of Robol in different breast tumors and its association with the breast cancer brain metastasis. Methods Labelled streptavidin-biotin (LSAB) staining was used to examine the Robol expression in specimens from 24 cases of invasive ductal carcinoma(IDC) with brain metastasis, 71 cases of IDC without brain metastasis, 22 cases of ductal carcinoma in situ (DCIS) and 23 eases of fibroadenoma. Results The expression pattern of Robol in DCIS (59.1%) and IDC (45.3%) was significantly lower than that in adenofibroma (87.0% , P 〈 0.05 ). The expression of Robol in IDC with brain metastasis ( 12.5% ) was significantly lower than that in IDC without brain metastasis (56.3% , P 〈 0.05). The expression of Robol was much higher in more than 50 year-old-group (57.8%) than that in less than 50 year-old-group (34.0%) of IDC patients. The overall survival time in patients with the Robol negative expression was significantly shorter than those with positive expression ( P 〈 0.05 ). No correlation was found between the Robol expression and the tumor size, lymph node metastasis, pathologic stage, histological grade and clinical stage (P 〉 0.05 ). Conclusions The Robol expression correlates negatively with IDC brain metastasis, and correlates positively with the age and prognosis of IDC patients. Robol may be applied as a marker in evaluation of the IDC prognosis and brain metastasis.